

### Characteristics of the 109 individual trials (2018 December update)

| Trials             | Treatment             | Sample size | Age | Male | Asian | Caucasian | Stage IV | Squamous | PS2 | Smokers | Second line | EGFR-WT or unknown <sup>a</sup> |
|--------------------|-----------------------|-------------|-----|------|-------|-----------|----------|----------|-----|---------|-------------|---------------------------------|
| ARCHER 1009, 2014  | Erlotinib             | 439         | 62  | 277  | 88    | 331       | 403      | 128      | 46  | 357     | 281         | 395                             |
| ARCHER 1009, 2014  | Dacomitinib           | 439         | 64  | 288  | 91    | 335       | 400      | 115      | 42  | 360     | 256         | 392                             |
| ARQ 197-209, 2011  | Erlotinib             | 83          | 62  | 49   |       |           | 72       | 24       | 0   | 65      | 51          | 72                              |
| ARQ 197-209, 2011  | Erlotinib+Tivantinib  | 84          | 64  | 51   |       |           | 76       | 31       | 1   | 67      | 50          | 78                              |
| ATTENTION, 2015    | Erlotinib+Tivantinib  | 154         | 63  | 109  | 154   | 0         | 118      | 0        | 0   | 113     | 92          | 154                             |
| ATTENTION, 2015    | Erlotinib             | 153         | 63  | 102  | 153   | 0         | 115      | 0        | 0   | 114     | 90          | 153                             |
| Bergqvist, 2014    | Docetaxel             | 41          | 58  | 31   |       |           | 40       | 20       | 1   |         |             | 41                              |
| Bergqvist, 2014    | AXL1717               | 58          | 57  | 40   |       |           | 52       | 29       | 3   |         |             | 58                              |
| Besse, 2014        | Erlotinib+Everolimus  | 66          | 60  | 36   | 7     | 54        | 64       | 10       | 0   | 61      | 51          | 66                              |
| Besse, 2014        | Erlotinib             | 67          | 60  | 33   | 2     | 57        | 63       | 10       | 0   | 64      | 41          | 67                              |
| BeTa, 2011         | Erlotinib             | 317         | 65  | 170  | 18    | 257       |          | 17       | 20  | 284     | 317         | 299                             |
| BeTa, 2011         | Erlotinib+Bevacizumab | 319         | 65  | 171  | 23    | 264       |          | 11       | 23  | 285     | 319         | 307                             |
| Bhatnagar, 2012    | Docetaxel             | 15          | 57  | 11   | 15    | 0         | 11       | 8        | 2   | 12      | 15          | 15                              |
| Bhatnagar, 2012    | Gefitinib             | 15          | 58  | 12   | 15    | 0         | 12       | 9        | 3   | 12      | 15          | 15                              |
| Blumenschein, 2015 | Docetaxel             | 45          | 61  | 23   | 10    | 35        |          | 1        | 1   | 38      | 45          | KRAS                            |
| Blumenschein, 2015 | Trametinib            | 89          | 61  | 46   | 11    | 74        |          | 0        | 0   | 83      | 89          | KRAS                            |
| BR21, 2005         | Placebo               | 243         | 59  | 160  | 28    | 188       |          | 78       | 56  | 201     | 121         | 175                             |
| BR21, 2005         | Erlotinib             | 488         | 62  | 315  | 63    | 379       |          | 144      | 126 | 384     | 243         | 371                             |
| CALGB 30704, 2014  | Pemetrexed+Sunitinib  | 41          | 63  | 22   | 1     | 32        | 38       | 6        | 0   |         | 39          | 41                              |
| CALGB 30704, 2014  | Pemetrexed            | 42          | 63  | 22   | 0     | 36        | 37       | 4        | 0   |         | 38          | 42                              |
| CALGB 30704, 2014  | Sunitinib             | 47          | 63  | 25   | 1     | 43        | 39       | 7        | 0   |         | 43          | 47                              |
| CheckMate017, 2015 | Nivolumab             | 135         | 62  | 111  | 4     | 122       | 105      | 135      | 0   | 125     | 135         | 135                             |
| CheckMate017, 2015 | Docetaxel             | 137         | 64  | 97   | 2     | 130       | 112      | 137      | 0   | 130     | 137         | 137                             |
| CheckMate057, 2015 | Docetaxel             | 290         | 62  | 168  | 8     | 266       |          | 0        | 0   | 230     | 259         | 252                             |
| CheckMate057, 2015 | Nivolumab             | 292         | 61  | 151  | 9     | 267       |          | 0        | 0   | 234     | 256         | 256                             |

|                                     |                          |     |    |     |     |    |     |    |    |     |     |     |
|-------------------------------------|--------------------------|-----|----|-----|-----|----|-----|----|----|-----|-----|-----|
| Chen, 2011                          | Tegafur/uracil+Gefitinib | 57  | 65 | 37  | 57  | 0  |     | 0  | 11 | 25  | 25  | 37  |
| Chen, 2011                          | Gefitinib                | 58  | 64 | 33  | 58  | 0  |     | 0  | 24 | 28  | 31  | 42  |
| CTONG0806, 2014                     | Pemetrexed               | 80  | 56 | 47  | 80  | 0  | 66  | 4  | 0  | 36  | 80  | 80  |
| CTONG0806, 2014                     | Gefitinib                | 81  | 58 | 54  | 81  | 0  | 77  | 2  | 0  | 48  | 81  | 81  |
| Dai, 2013                           | Gefitinib                | 23  | 62 | 15  | 23  | 0  | 19  | 0  | 6  | 13  | 23  | 23  |
| Dai, 2013                           | Pemetrexed               | 23  | 61 | 14  | 23  | 0  | 18  | 0  | 5  | 12  | 23  | 23  |
| DATE, 2015                          | Gefitinib+Nimotuzumab    | 78  | 63 | 54  |     |    |     | 27 | 3  |     | 78  | 66  |
| DATE, 2015                          | Gefitinib                | 77  | 63 | 48  |     |    |     | 27 | 0  |     | 77  | 62  |
| DELTA, 2014                         | Erlotinib                | 150 | 68 | 108 | 150 | 0  | 120 | 29 | 6  | 111 | 121 | 150 |
| DELTA, 2014                         | Docetaxel                | 151 | 67 | 107 | 151 | 0  | 122 | 32 | 6  | 114 | 130 | 151 |
| Dittrich, 2014                      | Pemetrexed+Erlotinib     | 79  | 64 | 46  | 1   | 75 | 64  | 0  | 9  | 69  | 79  | 79  |
| Dittrich, 2014                      | Pemetrexed               | 83  | 60 | 49  | 1   | 82 | 70  | 0  | 11 | 69  | 83  | 83  |
| E1512, 2015                         | Cabozantinib             | 40  | 66 | 14  | 0   | 33 | 24  | 0  | 4  | 34  | 23  | 38  |
| E1512, 2015                         | Erlotinib                | 42  | 66 | 18  | 2   | 32 | 29  | 0  | 5  | 37  | 23  | 38  |
| E1512, 2015                         | Erlotinib+Cabozantinib   | 43  | 64 | 18  | 0   | 31 | 25  | 0  | 4  | 37  | 21  | 35  |
| Esteban, 2003                       | Docetaxel                | 35  | 55 | 29  |     |    | 35  | 13 | 12 |     | 27  | 35  |
| Esteban, 2003                       | Paclitaxel               | 36  | 62 | 30  |     |    | 36  | 10 | 13 |     | 25  | 36  |
| Gerber, 2014*                       | Erlotinib+Tivantinib     | 51  | 64 | 17  |     |    |     |    |    |     | 22  | 51  |
| Gerber, 2014*                       | Chemotherapy             | 45  | 64 | 15  |     |    |     |    |    |     | 20  | 45  |
| GFPC 05-06, 2011                    | Docetaxel                | 75  | 59 | 64  |     |    | 59  | 23 | 5  |     | 78  | 75  |
| GFPC 05-06, 2011                    | Pemetrexed               | 75  | 58 | 62  |     |    | 62  | 18 | 4  |     | 75  | 75  |
| Groen, 2013                         | Erlotinib+Sunitinib      | 65  | 59 | 39  | 1   | 63 | 63  | 15 | 0  | 58  | 39  | 61  |
| Groen, 2013                         | Erlotinib                | 67  | 61 | 45  | 2   | 64 | 67  | 19 | 1  | 58  | 46  | 66  |
| Hainsworth, 2010                    | Selumetinib              | 40  | 62 | 26  | 0   | 39 |     | 25 |    | 34  | 31  | 40  |
| Hainsworth, 2010                    | Pemetrexed               | 44  | 64 | 27  | 1   | 42 |     | 24 |    | 32  | 35  | 44  |
| Han, 2011                           | Docetaxel                | 40  | 50 | 22  | 40  | 0  |     | 16 | 4  |     | 40  | 40  |
| Han, 2011                           | Pemetrexed               | 44  | 50 | 26  | 44  | 0  |     | 18 | 6  |     | 44  | 44  |
| HANSHIN OncologyGroup<br>0110, 2015 | Docetaxel+Bevacizumab    | 45  | 64 | 27  | 45  | 0  | 36  | 0  | 0  | 34  | 45  | 30  |

|                                   |                          |      |    |     |     |     |     |     |     |     |     |      |
|-----------------------------------|--------------------------|------|----|-----|-----|-----|-----|-----|-----|-----|-----|------|
| HANSHIN Oncology Group 0110, 2015 | S1+Bevacizumab           | 45   | 64 | 27  | 45  | 0   | 37  | 0   | 0   | 31  | 45  | 27   |
| Herbst, 2007*                     | Erlotinib+Bevacizumab    | 39   | 68 | 17  | 3   | 29  |     | 0   | 0   | 33  | 39  | 38   |
| Herbst, 2007*                     | Chemotherapy             | 41   | 65 | 25  | 1   | 31  |     | 0   | 1   | 35  | 41  | 41   |
| Herbst, 2007*                     | Chemotherapy+Bevacizumab | 40   | 64 | 23  | 2   | 34  |     | 0   | 0   | 36  | 40  | 40   |
| Heymach, 2007                     | Docetaxel+Vandetanib     | 42   | 61 | 21  | 0   | 42  | 28  | 12  | 0   | 35  | 42  | 42   |
| Heymach, 2007                     | Docetaxel                | 41   | 58 | 27  | 0   | 41  | 28  | 11  | 0   | 37  | 41  | 41   |
| Heymach, 2007                     | Docetaxel+Vandetanib 300 | 44   | 60 | 25  | 0   | 44  | 35  | 14  | 0   | 40  | 44  | 44   |
| HORG, 2013                        | Pemetrexed               | 178  | 66 | 138 | 0   | 178 | 147 | 36  | 31  | 154 | 101 | 178  |
| HORG, 2013                        | Erlotinib                | 179  | 65 | 135 | 0   | 179 | 154 | 39  | 18  | 150 | 89  | 179  |
| Hosomi, 2015                      | Docetaxel+Ramucirumab    | 79   | 66 | 59  | 76  | 0   |     | 9   | 0   | 65  | 76  | 76   |
| Hosomi, 2015                      | Docetaxel                | 81   | 65 | 62  | 81  | 0   |     | 9   | 0   | 67  | 81  | 81   |
| ICOGN, 2013                       | Gefitinib                | 199  | 56 | 114 | 199 | 0   | 162 | 36  | 21  | 97  | 107 | 160  |
| ICOGN, 2013                       | Icotinib                 | 200  | 56 | 118 | 200 | 0   | 162 | 34  | 26  | 99  | 126 | 171  |
| INTEREST, 2008                    | Gefitinib                | 733  | 61 | 466 | 154 | 550 |     | 185 | 86  | 585 | 619 | 711  |
| INTEREST, 2008                    | Docetaxel                | 733  | 60 | 488 | 169 | 540 |     | 176 | 84  | 583 | 610 | 711  |
| ISEL, 2005                        | Placebo                  | 563  | 61 | 378 | 107 | 431 | 450 | 187 | 145 | 438 | 274 | 563  |
| ISEL, 2005                        | Gefitinib                | 1129 | 62 | 761 | 235 | 843 | 896 | 399 | 332 | 879 | 549 | 1129 |
| ISTANA, 2010                      | Docetaxel                | 79   | 58 | 45  | 79  | 0   | 65  | 11  | 5   | 43  | 79  | 79   |
| ISTANA, 2010                      | Gefitinib                | 82   | 57 | 55  | 82  | 0   | 71  | 17  | 6   | 52  | 82  | 82   |
| Janne, 2013                       | Docetaxel                | 43   | 59 | 20  | 0   | 40  | 42  | 6   | 0   | 38  | 43  | KRAS |
| Janne, 2013                       | Docetaxel+Selumetinib    | 44   | 60 | 21  | 0   | 41  | 39  | 3   | 0   | 39  | 44  | KRAS |
| JMEI, 2004                        | Pemetrexed               | 283  | 59 | 194 | 64  | 207 | 212 | 78  | 30  |     | 283 | 283  |
| JMEI, 2004                        | Docetaxel                | 288  | 57 | 217 | 72  | 206 | 215 | 93  | 34  |     | 288 | 288  |
| Jones, 2008                       | Topotecan                | 39   | 63 | 23  |     |     |     |     | 1   |     | 39  | 39   |
| Jones, 2008                       | Docetaxel                | 41   | 62 | 23  |     |     |     |     | 6   |     | 41  | 41   |
| Juan, 2014                        | Docetaxel+Erlotinib      | 34   | 58 | 31  | 0   | 34  | 30  | 16  | 5   | 32  | 33  | 33   |
| Juan, 2014                        | Erlotinib                | 36   | 64 | 29  | 0   | 36  | 29  | 13  | 6   | 34  | 35  | 34   |
| Kapoor, 2015                      | Gefitinib                | 54   | 56 | 43  | 54  | 0   | 40  |     | 17  |     |     | 20   |

|                    |                      |     |    |     |     |     |     |     |    |     |     |     |
|--------------------|----------------------|-----|----|-----|-----|-----|-----|-----|----|-----|-----|-----|
| Kapoor, 2015       | Docetaxel            | 53  | 56 | 42  | 53  | 0   | 39  |     | 17 |     |     | 17  |
| Katakami, 2014     | Amrubicin            | 101 | 64 | 66  | 98  | 0   | 81  | 17  | 0  | 75  | 78  | 80  |
| Katakami, 2014     | Docetaxel            | 101 | 64 | 69  | 99  | 0   | 74  | 18  | 0  | 75  | 80  | 82  |
| KCSG-LU08-01, 2012 | Pemetrexed           | 70  | 64 | 10  | 70  | 0   | 61  | 0   | 6  | 0   | 70  | 46  |
| KCSG-LU08-01, 2012 | Gefitinib            | 71  | 58 | 10  | 71  | 0   | 62  | 0   | 6  | 0   | 71  | 49  |
| Kelly, 2012        | Pralatrexate         | 100 | 63 | 69  |     | 74  | 87  | 29  | 0  | 100 |     | 100 |
| Kelly, 2012        | Erlotinib            | 101 | 62 | 68  |     | 78  | 84  | 47  | 0  | 101 |     | 101 |
| KEYNOTE-010,2015   | Pembrolizumab2       | 344 | 63 | 212 | 73  | 246 |     | 76  | 3  | 281 | 243 | 316 |
| KEYNOTE-010,2015   | Pembrolizumab 10     | 346 | 63 | 213 | 72  | 250 |     | 80  | 1  | 286 | 235 | 320 |
| KEYNOTE-010,2015   | Docetaxel            | 343 | 62 | 209 | 72  | 251 |     | 66  | 2  | 276 | 235 | 317 |
| Kim A, 2012        | Pemetrexed+Cetuximab | 301 | 63 | 173 | 3   | 268 |     | 76  | 12 |     | 301 | 301 |
| Kim A, 2012        | Pemetrexed           | 304 | 64 | 188 | 6   | 265 |     | 71  | 14 |     | 304 | 304 |
| Kim B, 2012        | Docetaxel            | 166 | 64 | 93  | 2   | 141 |     | 51  | 11 |     | 166 | 166 |
| Kim B, 2012        | Docetaxel+Cetuximab  | 167 | 64 | 92  | 5   | 146 |     | 41  | 2  |     | 167 | 167 |
| Kim, 2015          | Pemetrexed           | 47  | 64 | 33  | 47  | 0   | 44  | 10  | 15 | 33  | 32  | 46  |
| Kim, 2015          | Gefitinib            | 48  | 67 | 35  | 48  | 0   | 46  | 9   | 17 | 33  | 30  | 47  |
| Krzakowski, 2010   | Vinflunine           | 274 | 62 | 205 |     |     | 247 | 100 |    |     | 274 | 274 |
| Krzakowski, 2010   | Docetaxel            | 277 | 60 | 208 |     |     | 248 | 95  |    |     | 277 | 277 |
| Kuo, 2013          | Docetaxel            | 6   | 54 | 3   | 6   | 0   |     | 0   | 1  |     | 6   | 6   |
| Kuo, 2013          | Gefitinib            | 8   | 67 | 4   | 8   | 0   |     | 0   | 0  |     | 8   | 8   |
| Lee, 2013          | Pemetrexed+Erlotinib | 78  | 56 | 20  | 58  | 20  | 72  | 0   | 7  | 0   | 78  | 78  |
| Lee, 2013          | Pemetrexed           | 80  | 56 | 35  | 68  | 12  | 68  | 0   | 4  | 0   | 80  | 80  |
| Lee, 2013          | Erlotinib            | 82  | 54 | 28  | 76  | 6   | 68  | 0   | 6  | 0   | 82  | 82  |
| Levy, 2014         | Docetaxel            | 47  | 60 | 24  |     | 34  | 45  | 12  | 0  |     |     | 47  |
| Levy, 2014         | Docetaxel+PX-866     | 48  | 65 | 33  |     | 39  | 45  | 8   | 0  |     |     | 48  |
| Li, 2010           | Docetaxel            | 48  | 48 | 29  | 48  | 0   | 19  | 27  |    |     | 48  | 48  |
| Li, 2010           | Gefitinib            | 50  | 51 | 30  | 50  | 0   | 21  | 22  |    |     | 50  | 50  |
| Li, 2012           | Docetaxel            | 128 | 56 | 74  | 102 | 0   | 61  | 25  |    |     | 102 | 128 |
| 132Li, 2012        | Pemetrexed           | 132 | 58 | 67  | 106 | 0   | 70  | 19  |    |     | 106 | 132 |

|                    |                       |     |    |     |     |     |     |     |    |     |     |     |
|--------------------|-----------------------|-----|----|-----|-----|-----|-----|-----|----|-----|-----|-----|
| Li, 2013           | Pemetrexed            | 27  | 62 | 14  | 0   | 18  |     | 0   | 3  | 22  | 27  | 27  |
| Li, 2013           | Pemetrexed+Erlotinib  | 52  | 64 | 23  | 2   | 36  |     | 0   | 5  | 35  | 52  | 45  |
| Li, 2014           | Erlotinib             | 61  | 54 | 40  | 61  | 0   | 40  | 0   | 4  | 46  | 61  | 61  |
| Li, 2014           | Pemetrexed            | 62  | 55 | 39  | 62  | 0   | 38  | 0   | 3  | 45  | 62  | 62  |
| Liu, 2015          | Pemetrexed            | 56  | 51 | 34  | 56  | 0   |     | 32  | 11 | 55  | 56  | 56  |
| Liu, 2015          | Nab-Paclitaxel        | 55  | 52 | 37  | 55  | 0   |     | 27  | 15 | 55  | 55  | 55  |
| LUME-COLUMBUS,2016 | Docetaxel+Nintedanib  | 6   | 63 | 4   |     |     |     |     |    |     |     | 6   |
| LUME-COLUMBUS,2016 | Docetaxel             | 6   | 60 | 5   |     |     |     |     |    |     |     | 6   |
| LUME-LUNG 1, 2014  | Docetaxel+Nintedanib  | 655 | 60 | 476 | 116 | 533 | 588 | 276 | 1  | 490 | 655 | 655 |
| LUME-LUNG 1, 2014  | Docetaxel             | 659 | 60 | 479 | 123 | 530 | 605 | 279 | 0  | 498 | 659 | 659 |
| LUME-LUNG 2, 2013  | Pemetrexed+Nintedanib | 353 | 60 | 195 | 103 | 225 | 307 | 3   | 0  | 244 | 353 | 336 |
| LUME-LUNG 2, 2013  | Pemetrexed            | 360 | 59 | 208 | 106 | 230 | 328 | 2   | 0  | 238 | 360 | 349 |
| Lux-Lung 8, 2015   | Erlotinib             | 397 | 64 | 331 | 86  | 311 | 345 | 382 | 1  | 379 | 397 | 397 |
| Lux-Lung 8, 2015   | Afatinib              | 398 | 65 | 335 | 86  | 312 | 349 | 381 | 3  | 372 | 398 | 398 |
| Maitland, 2014     | Cetuximab             | 20  | 62 | 14  | 0   | 13  |     | 6   |    | 18  |     | 20  |
| Maitland, 2014     | Pemetrexed+Cetuximab  | 23  | 55 | 13  | 1   | 17  |     | 8   |    | 21  |     | 23  |
| Marangolo, 2000    | Docetaxel             | 14  | 64 |     |     |     |     | 4   |    |     | 14  | 14  |
| Marangolo, 2000    | Vinorelbine           | 11  | 64 |     |     |     |     | 6   |    |     | 11  | 11  |
| MARQUEE, 2013      | Erlotinib             | 522 | 61 | 309 | 5   | 446 | 501 | 0   | 1  | 424 | 348 | 469 |
| MARQUEE, 2013      | Erlotinib+Tivantinib  | 526 | 62 | 310 | 8   | 430 | 499 | 0   | 1  | 425 | 346 | 470 |
| MARVEL, 2013       | Erlotinib             | 11  | 69 | 5   |     |     |     |     |    |     | 11  | 11  |
| MARVEL, 2013       | Pemetrexed            | 12  | 55 | 6   |     |     |     |     |    |     | 12  | 12  |
| METLung, 2014      | Erlotinib             | 249 | 63 | 140 | 37  | 180 |     | 31  | 3  |     | 157 | 220 |
| METLung, 2014      | Erlotinib+Onartuzumab | 250 | 62 | 140 | 35  | 182 |     | 40  | 5  |     | 161 | 222 |
| Moran, 2014        | Erlotinib+Dalotuzumab | 37  | 62 | 27  | 0   | 37  | 33  | 11  | 2  | 33  | 27  | 37  |
| Moran, 2014        | Erlotinib             | 38  | 59 | 28  | 2   | 36  | 29  | 6   | 1  | 27  | 20  | 38  |
| Natale, 2009       | Vandetanib            | 83  | 63 | 48  |     |     | 69  | 16  | 0  | 71  |     | 83  |
| Natale, 2009       | Gefitinib             | 85  | 61 | 52  |     |     | 63  | 22  | 0  | 77  |     | 85  |
| NCCTG N0626, 2011  | Pemetrexed+Sorafenib  | 47  | 62 | 27  |     |     | 39  | 0   | 0  |     |     | 47  |

|                      |                        |     |    |     |     |     |     |     |     |     |     |     |
|----------------------|------------------------|-----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| NCCTG N0626, 2011    | Pemetrexed             | 51  | 62 | 23  |     |     | 45  | 0   | 0   |     |     | 51  |
| NCIC CTG BR.26, 2014 | Placebo                | 240 | 66 | 120 | 70  | 144 | 212 | 44  | 58  | 155 | 64  | 172 |
| NCIC CTG BR.26, 2014 | Dacomitinib            | 480 | 64 | 244 | 141 | 288 | 443 | 63  | 119 | 306 | 133 | 366 |
| NVALT-10, 2013       | Erlotinib              | 115 | 64 | 75  |     |     | 86  | 40  | 9   | 108 | 115 | 115 |
| NVALT-10, 2013       | Erlotinib+Chemotherapy | 116 | 63 | 73  |     |     | 94  | 34  | 9   | 107 | 116 | 116 |
| OAK,2016             | Atezolizumab           | 613 | 63 | 378 | 124 | 302 |     | 161 | 0   | 501 | 464 | 553 |
| OAK,2016             | Docetaxel              | 612 | 64 | 379 | 125 | 296 |     | 160 | 0   | 516 | 465 | 559 |
| Paz-Ares, 2008       | Docetaxel              | 422 | 63 | 302 | 5   | 381 | 343 |     | 62  |     | 422 | 422 |
| Paz-Ares, 2008       | Paclitaxel             | 427 | 62 | 308 | 5   | 397 | 342 |     | 57  |     | 427 | 427 |
| POPLAR, 2016         | Atezolizumab           | 144 | 62 | 93  |     |     |     | 49  | 2   | 117 | 93  | 133 |
| POPLAR, 2016         | Docetaxel              | 143 | 62 | 76  |     |     |     | 48  | 1   | 114 | 96  | 135 |
| PROSE, 2014*         | Chemotherapy           | 142 | 64 | 91  |     |     | 110 | 16  | 8   | 125 | 142 | 123 |
| PROSE, 2014*         | Erlotinib              | 143 | 66 | 99  |     |     | 121 | 31  | 8   | 122 | 143 | 126 |
| Ramalingam, 2011     | Erlotinib              | 57  | 62 | 37  | 0   | 55  | 46  | 12  |     | 48  | 43  | 54  |
| Ramalingam, 2011     | Erlotinib+R15073W      | 57  | 62 | 38  | 0   | 56  | 50  | 16  |     | 52  | 39  | 56  |
| Ramalingam, 2011     | Erlotinib+R1507 W      | 58  | 63 | 39  | 0   | 55  | 50  | 15  |     | 50  | 44  | 56  |
| Ramalingam, 2012     | Dacomitinib            | 94  | 60 | 55  | 23  | 68  |     | 32  | 19  | 76  | 51  | 75  |
| Ramalingam, 2012     | Erlotinib              | 94  | 62 | 56  | 24  | 67  |     | 33  | 3   | 75  | 63  | 83  |
| Ramlau, 2006         | Topotecan              | 414 | 59 | 311 | 31  | 368 | 308 | 155 | 58  |     | 414 | 414 |
| Ramlau, 2006         | Docetaxel              | 415 | 59 | 310 | 39  | 359 | 298 | 181 | 65  |     | 415 | 415 |
| Ramlau, 2012         | Docetaxel+Aflibercept  | 456 | 60 | 305 | 34  | 411 | 414 | 0   | 21  |     | 456 | 456 |
| Ramlau, 2012         | Docetaxel              | 457 | 60 | 300 | 40  | 405 | 410 | 0   | 23  |     | 457 | 457 |
| REVEL, 2014          | Docetaxel              | 625 | 61 | 415 | 86  | 503 |     | 171 | 0   | 484 | 625 | 607 |
| REVEL, 2014          | Docetaxel+Ramucirumab  | 628 | 62 | 419 | 74  | 526 |     | 157 | 0   | 519 | 628 | 613 |
| Sbar, 2010           | Erlotinib              | 70  |    | 50  |     |     |     | 17  |     | 61  |     | 70  |
| Sbar, 2010           | BMS-690514             | 71  |    | 50  |     |     |     | 18  |     | 61  |     | 71  |
| Scagliotti, 2012     | Erlotinib+Sunitinib    | 480 | 61 | 297 | 52  | 412 | 438 | 135 | 1   | 384 | 340 | 480 |
| Scagliotti, 2012     | Erlotinib              | 480 | 61 | 284 | 51  | 413 | 448 | 135 | 0   | 390 | 340 | 480 |
| Scagliotti, 2014     | Erlotinib              | 290 | 62 | 225 | 23  | 238 | 235 | 263 | 54  | 264 |     | 290 |

|                        |                          |     |    |     |     |     |     |     |    |     |     |      |
|------------------------|--------------------------|-----|----|-----|-----|-----|-----|-----|----|-----|-----|------|
| Scagliotti, 2014       | Erlotinib+Figitumumab    | 293 | 62 | 228 | 21  | 249 | 230 | 263 | 56 | 277 |     | 293  |
| Schiller, 2010         | Pemetrexed+Matuzumab     | 49  | 63 | 27  | 0   | 47  | 41  | 17  | 0  |     | 49  | 49   |
| Schiller, 2010         | Pemetrexed               | 50  | 61 | 33  | 0   | 47  | 44  | 18  | 0  |     | 50  | 50   |
| Schiller, 2010         | Pemetrexed+Matuzumab 800 | 51  | 62 | 35  | 0   | 47  | 42  | 11  | 0  | 51  | 51  | 51   |
| SELECT 1,2017          | Docetaxel                | 256 | 61 | 145 | 4   | 243 | 246 | 14  | 0  | 235 | 256 | KRAS |
| SELECT 1,2017          | Docetaxel+Selumetinib    | 254 | 62 | 158 | 1   | 241 | 239 | 14  | 0  | 238 | 254 | KRAS |
| SIGN, 2006             | Gefitinib                | 68  | 63 | 47  | 0   | 61  | 41  |     | 25 | 50  | 68  | 68   |
| SIGN, 2006             | Docetaxel                | 73  | 60 | 51  | 0   | 61  | 41  |     | 21 | 55  | 73  | 73   |
| Spigel, 2011           | Erlotinib                | 56  | 65 | 26  | 0   | 47  |     | 17  | 10 | 48  | 28  | 53   |
| Spigel, 2011           | Erlotinib+Sorafenib      | 112 | 65 | 62  | 0   | 97  |     | 33  | 13 | 93  | 73  | 110  |
| Spigel, 2012           | Erlotinib                | 67  | 67 | 39  |     |     |     |     |    |     | 43  | 67   |
| Spigel, 2012           | Erlotinib+Pazopanib      | 134 | 66 | 71  |     |     |     |     |    |     | 64  | 134  |
| Spigel, 2013           | Erlotinib                | 68  | 63 | 42  | 1   | 61  |     | 20  | 2  | 60  | 46  | 62   |
| Spigel, 2013           | Erlotinib+Onartuzumab    | 69  | 64 | 40  | 2   | 61  |     | 20  | 4  | 59  | 46  | 62   |
| Sun, 2013              | Docetaxel                | 104 | 56 | 61  | 104 | 0   | 84  | 25  | 11 | 55  | 104 | 104  |
| Sun, 2013              | Pemetrexed               | 107 | 57 | 73  | 107 | 0   | 81  | 27  | 12 | 57  | 107 | 107  |
| TAILOR, 2013           | Docetaxel                | 110 | 67 | 73  | 1   | 109 | 103 | 23  | 7  | 80  | 102 | 110  |
| TAILOR, 2013           | Erlotinib                | 112 | 66 | 77  | 1   | 108 | 103 | 31  | 9  | 93  | 100 | 109  |
| TALISMAN, 2015         | Docetaxel+Erlotinib      | 37  | 66 | 36  |     |     |     | 37  | 0  | 37  | 37  | 37   |
| TALISMAN, 2015         | Erlotinib                | 36  | 68 | 36  |     |     |     | 36  | 1  | 36  | 36  | 36   |
| TAX 317, 2000          | Placebo                  | 49  | 61 | 32  |     |     | 40  |     | 12 |     | 37  | 49   |
| TAX 317, 2000          | Docetaxel                | 55  | 61 | 35  |     |     | 40  |     | 14 |     | 44  | 55   |
| TITAN, 2012*           | Chemotherapy             | 221 | 59 | 160 | 26  | 190 | 170 | 77  | 46 | 177 | 221 | 211  |
| TITAN, 2012*           | Erlotinib                | 203 | 59 | 161 | 28  | 172 | 162 | 77  | 39 | 173 | 203 | 195  |
| TORI L-03, 2013        | Erlotinib+Fulvestrant    | 50  |    |     |     |     |     |     |    |     |     | 50   |
| TORI L-03, 2013        | Erlotinib                | 50  |    |     |     |     |     |     |    |     |     | 50   |
| ULTIMATE-IFCT1103,2016 | Paclitaxel+Bevacizumab   | 111 | 60 | 78  |     |     |     | 11  | 8  | 102 | 76  | 111  |
| ULTIMATE-IFCT1103,2016 | Docetaxel                | 55  | 60 | 42  |     |     |     | 4   | 4  | 46  | 39  | 55   |

[illegible]

|                         |                              |            |           |            |            |            |  |            |          |            |            |  |
|-------------------------|------------------------------|------------|-----------|------------|------------|------------|--|------------|----------|------------|------------|--|
| <i>JAVELIN, 2018</i>    | <i>Avelumab</i>              | <i>396</i> | <i>64</i> | <i>269</i> | <i>102</i> | <i>294</i> |  | <i>120</i> | <i>0</i> | <i>326</i> | <i>351</i> |  |
| <i>JAVELIN, 2018</i>    | <i>Docetaxel</i>             | <i>396</i> | <i>63</i> | <i>273</i> | <i>114</i> | <i>282</i> |  | <i>122</i> | <i>0</i> | <i>333</i> | <i>353</i> |  |
| <i>ABOUND 2L+, 2018</i> | <i>Nab-Paclitaxel+CC-486</i> | <i>81</i>  | <i>65</i> | <i>50</i>  | <i>0</i>   | <i>81</i>  |  | <i>0</i>   | <i>0</i> | <i>72</i>  | <i>81</i>  |  |
| <i>ABOUND 2L+, 2018</i> | <i>Nab-Paclitaxel</i>        | <i>80</i>  | <i>63</i> | <i>50</i>  | <i>2</i>   | <i>78</i>  |  | <i>0</i>   | <i>0</i> | <i>76</i>  | <i>80</i>  |  |

\* Trials in which patients in the control arm received chemotherapy (e.g., docetaxel or pemetrexed) at the investigators' discretion;

¤ During the trial, some patients have been detected for EGFR mutation so we provided the number of patients excluding patients identified EGFR positive

In *blue italic bold* are the results of the 2018 update